Physician profile
Leo E Eickhoff
NPI 1871609966
$4,473.41
in general payments reported to CMS, 2019-2025
20 companies · $540 in 2025
The $540 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $566 · 2021: $833 · 2022: $776 · 2023: $555 · 2024: $771 · 2025: $540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,151.38 | 2019-2025 | |
| Janssen Biotech, INC. | $476.66 | 2019-2025 | Stelara, Tremfya |
| Takeda Pharmaceuticals U.S.A., INC. | $440.18 | 2019-2024 | Entyvio, Gattex |
| Celgene Corporation | $267.12 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.21 | 2019-2024 | Plenvu, Xifaxan |
| Pfizer INC. | $139.16 | 2019-2025 | |
| Lilly USA, LLC | $137.89 | 2024-2025 | Omvoh |
| Qol Medical, LLC | $106.80 | 2019-2020 | |
| Braintree Laboratories, INC. | $97.19 | 2019-2025 | Sutab, Suflave |
| Intercept Pharmaceuticals, INC. | $76.64 | 2020-2024 | |
| Genzyme Corporation | $59.11 | 2023-2024 | |
| Nestle Healthcare Nutrition INC. | $55.03 | 2021-2023 | |
| Ipsen Biopharmaceuticals, INC | $54.52 | 2025 | Iqirvo |
| Allergan, INC. | $51.51 | 2019-2020 | |
| Boston Scientific Corporation | $48.25 | 2024 | Resolution 360 Clip |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $44.98 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $26.65 | 2023 | Dupixent |
| Alfasigma USA, INC. | $20.59 | 2021 | |
| Organon LLC | $16.83 | 2023 | Hadlima |
| Merck Sharp & Dohme LLC | $16.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leo Eickhoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.